The U.S. also endured its highest flu-related hospitalization rates in almost 15 years last flu season, with unvaccinated ...

Researchers found an association between increased activity in a reward region of the brain—primarily stimulated by hopeful thinking—and heightened levels of protective antibodies after receiving a va ...

In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.63%, and the tech-heavy Nasdaq gained ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...

Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax (NASDAQ:NVAX) got a lift early Tuesday after the vaccine maker landed a licensing deal with Pfizer that puts its Matrix-M adjuvant to work in Pfizer's pipeline. Shares of Novavax were up about ...

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing ...

Health Secretary RFK Jr. removed four members of the Advisory Commission on Childhood Vaccines, which advises on Vaccine ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up ...